New hope for young women with chemo-resistant pregnancy cancer
NCT ID NCT03135769
Summary
This study tested whether the immunotherapy drug avelumab could help women with a rare, pregnancy-related cancer called gestational trophoblastic neoplasia (GTN) that had stopped responding to standard chemotherapy. The trial involved 24 women whose cancer was resistant to prior treatments. Researchers gave them avelumab to see if it could normalize their hormone levels (hCG) and control the disease, offering a potentially less toxic alternative to harsh chemotherapy.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GESTATIONAL TROPHOBLASTIC NEOPLASIAS (GTN) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Aphp Hopital Tenon
Paris, 75020, France
-
Centre Francois Baclesse
Caen, 14000, France
-
Hospices Civils de Lyon - CHLS
Pierre-Bénite, 69495, France
-
Institut Bergonie
Bordeaux, 33000, France
-
Institut Paoli-Calmettes
Marseille, 13000, France
-
Institut Universitaire Du Cancer de Toulouse - Oncopole
Toulouse, 31000, France
Conditions
Explore the condition pages connected to this study.